Pneumococcal Vaccination at Birth in High-Risk Infants
Author Information
Author(s): Anita H.J. van den Biggelaar, William Pomat, Anthony Bosco, Suparat Phuanukoonnon, Catherine J. Devitt, Marie A. Nadal-Sims, Peter M. Siba, Peter C. Richmond, Deborah Lehmann, Patrick G. Holt
Primary Institution: Telethon Institute for Child Health Research, University of Western Australia
Hypothesis
Can neonatal pneumococcal conjugate vaccination protect high-risk infants against severe disease and mortality?
Conclusion
Neonatal pneumococcal conjugate vaccination is safe and does not induce immunological tolerance.
Supporting Evidence
- Children vaccinated at birth showed higher immune responses compared to unvaccinated children.
- Hospitalization rates did not differ between vaccinated and unvaccinated groups.
- Neonatal vaccination induced similar immune memory responses as vaccination starting at one month.
Takeaway
Giving a pneumonia vaccine to newborns can help keep them safe from getting really sick, and it works just as well as giving it to older babies.
Methodology
Infants were randomized to receive the vaccine at birth or later, and immune responses were measured at 3 and 9 months.
Potential Biases
Potential bias due to loss of follow-up and parental consent withdrawal.
Limitations
The study was not powered to demonstrate clinical benefits of neonatal vaccination due to small blood volumes for immunological tests.
Participant Demographics
Newborns from Papua New Guinea, with a birth weight of at least 2000g and no acute infections.
Statistical Information
P-Value
0.044 for IL-5, 0.051 for IL-13
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website